Office of the Dean
These are extraordinary times, and the Yale School of Public Health (YSPH) is ready to meet the challenges and seize the opportunities to advance social justice and health equity for all with curriculum reform, emphasis on research on systemic racism and health, and application of discoveries to practice.
Our school’s world-renowned infectious disease epidemiologists, modelers, and disease control experts are advising local, state, national, and international governments and agencies on the COVID-19 response. The faculty’s innovation and expertise are on full display as they work to develop novel coronavirus testing assays, methods, and detection devices; equitable vaccine and health care policies, and epidemiologically guided solutions to control the pandemic.
Systemic racism is a centuries-old public health crisis. We are committed to educating and empowering current and future generations of public health professionals with an ethos of social justice and equity across all sectors. Our new U.S. Health Justice Concentration is launching this fall to complement the myriad of school-wide efforts to integrate diversity, equity, and inclusion in all that we do. This multi-disciplinary course of study allows students to analyze and address systems and processes that perpetuate health injustice in the United States, with attention to systemic racism as a key social determinant of disease.
We continue study and action to confront the unprecedented crisis in the warming and environmental degradation of our planet. YSPH was the first to offer an online certificate in Climate
Change and Health through our Yale Center on Climate Change and Health. This fall, the new Climate Change and Health Concentration is available to students of all disciplines and aims to address the shortage of public health professionals with the educational background needed to confront this existential threat.
We are at the forefront of discovery, prevention and, mitigation of disease, injury, disability, and stigma, and we hope you will share our mission toprotect and improve the health of the public.
Public health solutions are inherently interdisciplinary, and Yale University is a laboratory for innovation. A critical component of the YSPH experience is knowing the value of collaboration. Please explore our accessible partnerships across YSPH departments, with Yale’s other extraordinary schools, and within our own 545 students, 180 staff, and 144 full-time faculty. We now extend our academic reach with 12 joint-degree programs in coordination with the other graduate and professional schools at Yale, degree partnership programs with four universities overseas, and emerging distance learning and continuing education opportunities. Our coursework is enriched by our new curriculum designed for the modern public health professional driven by experiential learning.
By harnessing technology and cultivating unique partnerships, we are expanding shared resources and fostering exchanges through our centers and initiatives in innovative social entrepreneurship, global health, mathematical modeling of infectious diseases, child and maternal health, climate change and health, implementation science methods, environmental issues in child health, LGBTQ mental health and stigma, and the humanities and arts in public health, to name a few. Local, regional, and global partnerships ensure YSPH can improve the impact of public health and disease prevention. The school has revitalized its strategic foci in support of cutting-edge research, diversity and inclusion, and equitable public health practice.
Founded in 1915 as one of the original U.S. schools of public health, we have evolved into a highly collaborative, innovative, and student-oriented professional school that continues to foster a vibrant, inclusive environment. Our work is rooted in our core values of discovery, application, and service, and YSPH’s excellence is built upon the collective achievements of our diverse community. Follow us through our website and social media, and welcome to our community!
Towards a healthier and just future,
Sten H. Vermund
Dean and Anna M.R. Lauder Professor of Public Health
Associate Professor of Epidemiology (Chronic Diseases); Associate Dean for Diversity, Equity, and Inclusion, YSPH; Track Director, Applied Analytical Methods and Epidemiology, Online Executive MPH Program; Director, Advanced Professional MPH Program; Core Faculty, National Clinician Scholars Program
Associate Dean of Research and Professor of Epidemiology (Chronic Diseases); Associate Cancer Center Director (Population Sciences), Yale Cancer Center; Co-Leader, Cancer Prevention and Control, Yale Cancer Center; Deputy Director (Public Health), Yale Center for Clinical Investigation
The Yale School of Public Health Leadership Council is comprised of a diverse and distinguished group of alumni and friends who have demonstrated through their careers, interests, and engagement with the school and university a commitment to promote health and prevent disease. The Council advances the school’s continued development as a global leader in public health. Its members support the Dean to strategically enhance the school’s ability to provide a superb education to its students, conduct innovative and significant research, and improve health through effective and sustainable programs.
Leadership Council Members
Elaine Anderson, ’76 M.P.H., Ex officio serves as Co-chair of the YSPH Alumni Fund and is a member of the Board of Directors of the Association of Yale Alumni in Public Health (AYAPH). Elaine was Director of Community, Alumni and Special Studies at the Yale School of Public Health until her retirement in 2007. Her office had responsibility for a number of functions including institutional research; the school’s reaccreditation; strategic planning; public health practice; alumni relations; continuing education and workforce development; and special projects. Her previous position at Yale was as Director of the Resource Center for Health Professions Development.
A graduate of the Yale University School of Public Health, and the Institute for Social Policy Studies at the University of Michigan, her academic interests are in methodology/research design in community-based studies. She taught an applied community research course for MPH students at Yale for 25 years and still gives lectures on public health issues, primarily for the residential colleges.
Her publications and professional presentations have been on topics related to minority health, gender issues in health care, workforce development, public health practice, and changing global values as they relate to health behaviors.
Roger Barnett is the Chairman and CEO of Shaklee Corporation and the Managing Partner of Activated Holdings LLC. Founded in 1956, Shaklee is the number one natural nutrition and green cleaning products company in the U.S., with more than 1.2 million members and distributors in the U.S., Japan, Mexico, Malaysia, Canada, Taiwan, and China. In 2000, Shaklee was the first company in the world to become Climate Neutral Certified to fully offset its carbon emissions. Mr. Barnett began his career at the investment banking firm Lazard Freres & Co. He then organized an investment group to acquire control of Arcade, Inc., which he transformed into the largest sampling company in the world, expanding from a solely U.S. operation into a global business. He was also the founder and Chairman and CEO of Beauty.com, which continues to be one of the leading internet retailers in the cosmetics industry. In addition, Mr. Barnett is the Managing Partner of Activated Holdings LLC, an investment vehicle for a private family holding company, controlling more than $2 billion in assets. Mr. Barnett received his undergraduate degree from Yale College (Summa Cum Laude), his law degree from Yale Law School (Senior Editor, Yale Law Journal), and his MBA from Harvard Business School. Mr. Barnett has been selected as a Global Leader for Tomorrow by the World Economic Forum (Davos). He has also been selected as a Young Leader Fellow of the National Committee on U.S.-China Relations and is a member of the Young President’s Organization. Additionally, Mr. Barnett serves as a member of the Harvard School of Public Health Leadership Council, the Health Advisory Council of Columbia Presbyterian Hospital, the Yale University President's Council on International Activities, the Board of Directors of the Elie Wiesel Foundation for Humanity, the Advisory Board of 2004 Nobel Peace Laureate Wangari Maathai's The Green Belt Movement, the Board of Directors of the Metropolitan Opera Association, and the Board of Trustees of The Fine Arts Museums Foundation of San Francisco.
Andrew K. Bhak is Managing Director, Group Head in Healthcare Investment Banking at BMO Capital Markets, which follows three years at J.P. Morgan, where he was responsible for the healthcare services sector. He joined J.P. Morgan from Deutsche Bank, where he was Co-Head of Healthcare Services Investment Banking. Prior to that, Andrew was at Morgan Stanley, where he served in a similar capacity and helped to build its healthcare services investment banking franchise. He has served as advisor on more than $135 billion of financing and merger & acquisitions transactions, including HMA's $7.6 billion sale to Community Health Systems, HCA's $3.8 billion IPO, US Oncology's $2.1 billion sale to McKesson, and Quest Diagnostics' $2.0 billion acquisition of Ameripath, among others. Andrew also serves on the Advisory Board of the Yale Healthcare Conference.
Marna Borgstrom has served as the Chief Executive Officer of Yale New Haven Hospital and Yale New Haven Health since 2005. With revenues of more than $5.5B, Yale New Haven Health is the largest health system in the region. Marna began her career at Yale-New Haven Hospital over 40 years ago and served in a variety of staff and operational roles prior to her current position.
Marna chairs the board of the Healthcare Institute and is the past chair of the Coalition to Protect America’s Healthcare and Vizient, a Dallas, Texas-based health care company. She serves on several other boards including the American Hospital Association, the Connecticut Hospital Association and New Haven Promise. She is also a director of Cryolife in Atlanta, GA.
Marna has been recognized for her commitment to community service and the health care field with numerous awards. She also holds five honorary doctorate degrees.
Marna received her undergraduate degree from Stanford University and was awarded a master’s of public health by the Yale University School of Epidemiology and Public Health. She is a lecturer at the Yale School of Epidemiology and Public Health, from which she received the Distinguished Alumni Award in 2018.
Dr. Canny has extensive experience as a nonprofit leader in the Greater New Haven community for many decades. Most recently, she was the senior vice president for Grantmaking and Strategy at The Community Foundation for Greater New Haven until 2014. Dr. Canny led The Community Foundation’s efforts to use community knowledge and information to mobilize giving in the community and to advance Foundation efforts to strengthen the Greater New Haven region. She was also responsible for The Community Foundation’s grantmaking programs, nonprofit technical assistance and leadership initiatives, as well as community outreach.
Prior to coming to The Community Foundation, she worked for a decade at Connecticut Voices for Children, a research-based policy and advocacy organization, as director of research, and in the later years, as managing director and chief operating officer. Areas of research included child poverty, children and youth indicator reports, immigration as well as educational and health disparities. Before joining Connecticut Voices for Children, Dr. Canny was assistant dean for the Yale School of Public Health where she earned a Ph.D. in Chronic Disease Epidemiology. She was also a research scientist at YSPH for many years. She maintains an appointment at YSPH and serves on its Leadership Council, Stolwijk Scholarship Committee and Centennial Committee.
After college, Dr. Canny served in the Peace Corps in Togo, West Africa as a health educator.
Currently, Dr. Canny continues to serve as the President of the Board of Datahaven, an online comprehensive source for data about the Greater New Haven area. Datahaven's recent report is a comprehensive indicator report for the Greater New Haven area. She is also co-chair of the Community Impact Committee at United Way and on the Board of New Hytes.
James B. Crystal, ’86 B.A., is a Managing Director at Tricadia Capital Management, an investment firm that manages credit-focused hedge funds and related accounts. Prior to joining Tricadia, he was a Managing Director at Rockefeller & Co., one of the largest multi-family offices. Before joining Rockefeller in 2008, Jim was a Senior Managing Director and Portfolio Manager at Bear Stearns Asset Management, a Managing Director at Silverback Asset Management and, from 1997 to 2004, a Senior Managing Director at Bear, Stearns & Co., serving in the Investment Banking Department and the Asset-Backed Investments Group. Prior to joining Bear Stearns, he was a Director at predecessor companies to UBS Investment Bank from 1988 to 1997. He serves as the Treasurer of the American Friends of Herculaneum, a non-profit organization promoting education, conservation and research relating to the ancient Roman town of Herculaneum (now a World Heritage Site), which was buried and preserved by the eruption of Mount Vesuvius in 79 A.D. Jim received his B.A. magna cum laude from Yale College in 1986 and an A.M. from Harvard University in 1988.
Thomas Dubin ’19 MPH is a pharmaceutical executive and attorney. From 2001 through 2013 he was the Chief Legal Officer and a member of the core executive team that grew Alexion Pharmaceuticals from development stage to membership in the S&P 500. At Alexion, Tom led legal, government affairs, pricing and reimbursement, corporate communications, and other functions, and he held commercial responsibility for the company’s Australasia region. Prior to Alexion, Tom served as Vice President, General Counsel and Secretary of ChiRex, Inc., an international corporation providing advanced process development services and specialty manufacturing to the pharmaceutical industry. Tom began his career as a corporate attorney with Cravath, Swaine & Moore in New York City. He is a past Director of BioBlast Pharmaceuticals (NASD: ORPN), on the Advisory Board of Mythic Pharmaceuticals, Trustee of American Jewish World Service, and has been elected Vice Chair of Norwalk Hospital (term begins January, 2020). He received his J.D. from New York University School of Law, where he received the American Jurisprudence Prize in securities law, and his B.A. from Amherst College, cum laude.
David Dull, ’71 B.A., ’82 J.D., is a director of Ostendo Technologies, Inc. and OnRamp Wireless, Inc. and a business advisor to several other privately-held electronics, water science and bioscience companies. In 2009, he retired after 11 years as a senior executive and general counsel of Broadcom Corporation, where he was responsible for legal affairs, intellectual property strategy and development, and mergers and acquisitions. Previously, as a partner in the law firm of Irell & Manella LLP, he represented clients in the entertainment and technology industries. For five years before and after law school, Mr. Dull was a staff member of the United Nations Association of the U.S.A., a non-profit research and advocacy organization. Mr. Dull is a trustee of Sage Hill School and Sarah Lawrence College and a former member of the Yale Law School Association Executive Committee. He and his wife reside in Newport Beach, CA. They have two children.
Kathe Fox, Ph.D., Ex officio serves as President of the Board of Directors of the Association of Yale Alumni in Public Health (AYAPH). Dr. Fox is a member of Aetna’s Analytics and Behavior change organization and leads the Informatics activities that support Plan Sponsor analyses and tools. Recently Kathe led the design and assessment of provider and network services including the assessment and monitoring of Aetna’s Joint Venture partners. Kathe also helps manage data governance for external release of Aetna data for research. Recently Kathe won the 2016 Aetna Innovator of the Year Award and the Aetna Chairman’s Award for her Health/Wealth product idea.
Over the last six years Kathe has worked closely with the Harvard Medical School, specifically the Departments of Biomedical Informatics and Health Policy, and encouraged and supported the growth of clinical and policy research using health insurance claims data. Harvard and Aetna have built a multi-year data enclave that offers claims experience on 30+ M members over six years. Researchers have used these data to investigate questions ranging from the efficacy of preventive screening to the inheritability of autism. These data, and the associated analytic techniques, have been introduced to medical students as part of their training.
Prior to joining Aetna, Kathe was Vice President and Practice Leader for Health Plan customers at Medstat (now Truven Health Analytics) where she was responsible for analytic and consulting solutions for the managed care market. She also led a number of federal contracts including the CMS Medicaid Encounter Data Quality and Performance Measurement project and an AHRQ Medical Errors Reporting Implementation Plan.
Kathe holds a Ph.D. from Yale University (Department of Epidemiology and Public Health) and a B.A. in History from Skidmore College. She is a member of the Scientific Advisory Board of axialhealthcare, and an advisor, on behalf of Aetna, to Springboard Enterprises.
Mark Greenwold, B.A. ’66, is an attorney in Washington, D.C. and Senior Consultant to the Campaign for Tobacco-Free Kids, the leading global and national advocacy organization for tobacco control. Mr. Greenwold advises the Campaign on federal and state regulatory issues and represents a coalition of national public health groups in litigation regarding tobacco control. Mr. Greenwold also represents States and local governments in litigation against the tobacco industry. Previously, Mr. Greenwold served as the first Chief Counsel for Tobacco for the National Association of Attorneys General, where he represented all the States in the implementation and defense of the tobacco Master Settlement Agreement of 1998. Mr. Greenwold had previously spent 27 years in private practice in Washington specializing in complex civil litigation. While in private practice he worked with the Washington Lawyers Committee for Civil Rights and Urban Affairs on matters ranging from asylum to disability rights.
Mr. Greenwold graduated from Yale with a B.A. degree magna cum laude in History, the Arts and Letters in 1966 and from Harvard Law School with a J.D. degree cum laude in 1969. Mr. Greenwold served on the Board of Governors of the Association of Yale Alumni and is a past President of the Yale Club of Washington. He is also classical pianist. He and his wife, Betty, reside in Washington, D.C. They have three children, Amanda, B.A. ’92, J.D. ’98, an attorney in Washington; Simon, B.S. ’95, a computer engineer in Boston; and Diana, B.A. ’05, an art museum curator in Portland, Maine. They also have five grandchildren.
Clarion E Johnson, ‘76 M.D., retired from ExxonMobil Corporation as its Global Medical Director. He is presently The Chair of The Joint Commission’s International and Resource Boards. He is a Board member of The Milbank Memorial Fund Board and its Executive Committee. In addition, he is a member of The Catholic Medical Mission Board and The Quality Assurance Committee of The Bon Secours Hospital System.
He is a member of The National Academies Global Health Board and co-chairs its public private partnership initiative. He has a HHS Secretary appointment to The NIOSH (National Institute of Occupational Safety and Health) Advisory Board and was a member of Virginia Governor's Task Force on Health Reform and co-chair, Insurance Reform Task Force.
He is the past chair of Virginia Health Care Foundation, and the Board of City Lights Charter School in Washington DC. He served as advisor and lecturer in the Harvard Medical School’s Department of continuing education "Global Clinic Course" 2005-2008. In 2013, he received the President’s Award from the Oil and International Petroleum Industry Environment Conservation Association (IPIECA) and Oil and Gas Producers (OGP) for contributions to health and in 2012 he was the recipient of the Society of Petroleum Engineers (SPE) Award for Health, Safety, Security, Environment and Social Responsibility. In 2011 he received a medal from the French Army’s Institute De Recherche Biomedical for "Project Tetrapole:" a public private partnership in malaria research. He is a graduate of Sarah Lawrence College, and member of its Board of Trustees, and the Yale School of Medicine. While on active duty in the U.S. Army, he also trained as a microwave researcher at Walter Reed Army Institute of Research. He is Board Certified in Internal Medicine, Cardiology and Occupational Medicine.
Mary G. Lawrence, M.D., ’98 M.P.H., is the Deputy Director of the Department of Defense/Veterans Affairs Vision Center of Excellence in Washington, DC. The center focuses on research, clinical care integration, education, information systems, and advocacy related to vision trauma, especially injuries and diseases of the eyes and visual system incurred while on Active Duty. Previously, Dr. Lawrence was a member of the faculty at University of Minnesota where she served on the Glaucoma Service and directed the Visual Rehabilitation Service. While in Minnesota, she was also the Associate Chief of Ophthalmology at the Minneapolis Veterans Affairs Medical Center. Prior to this time, Dr. Lawrence served at Harvard Medical School where she received the Residents Teacher of the Year Award and the Dean’s Commendation for her teaching. Later she was awarded a Clinical Epidemiology Fellowship at Yale University School of Medicine as a Robert Wood Johnson Clinical Scholar. She received her B.A. in Chemistry from Mount Holyoke College and her M.D. from Jefferson Medical College in Philadelphia. Dr. Lawrence lives in Washington DC, and in NYC with her husband, James A. Lawrence, ’74 B.A., Chief Executive Officer of Rothschild North America, in NY. They have three children.
Harry Levitt, ‘71 B.A. Harry retired in 2018 and was a partner with MullinTBG (a national executive benefits consulting firm). He has more than 40 years of experience in corporate finance, investments, financial analysis and corporate treasury activities. Before joining MullinTBG, he worked on Wall Street, where he specialized in developing and executing investment strategies for large qualified pension plans. His corporate treasury and finance work included more than 10 years as a corporate pension plan sponsor.
He was a frequent speaker on executive benefits and compensation topics. He was an instructor at Pepperdine University teaching finance in the MBA program and has previously been a lecturer at UCLA and the University of Southern California. Harry was on the Board of the City of Hope, a leading cancer and diabetes research and treatment center in Duarte, California, where he served on the Audit and Compensation Committees. Harry graduated from Yale University with a Bachelor of Arts degree in Economics. He received a Master of Business Administration from Harvard University. He is a Registered Representative of M Holdings Securities, Inc., a Registered Broker Dealer, Member of NASD/SIPC.
Jennifer Weis Monsky, ’91 MA, is an Executive Editor at St. Martin's Press in NYC. During her tenure there, she has acquired and published many health-related books including most recently CLIMATE OF HOPE by Michael Bloomberg and Carl Pope, HOW CAN I GET BETTER by Dr. Richard Horowitz and DIRT IS GOOD by Drs. Jack Gilbert and Rob Knight. She is also known for her fiction bestsellers, among them THE NANNY DIARIES, SARAH'S KEY, THE HOUSE OF NIGHT and BEHIND CLOSED DOORS. Jennifer became interested in public health through her personal experiences with Lyme Disease. She joined the Columbia Lyme and Tick-borne Diseases Research Center board in 2008, and served as its chair for 3 years. She became a pioneering member of the Gray Matters program at Columbia and continues to serve on its board. This program is devoted to funding young Fellows in Psychiatry. Additionally, she is a member of the Columbia University Psychiatry Board. As various advocacy groups have worked on addressing the Lyme Disease problem, Jennifer has participated in their national fundraising and strategic activities from both leadership and board member positions. Currently, she is on the Executive Board of Project Lyme based in NYC. She is also a member of the UJA Publishing Executive Committee. Jennifer received her BA and MA (in English) from Yale. She is married to John Monsky, Yale '81, and is the mother of 4 children.
Dr. Rock G. Positano is the Founder and Director of the Non-Surgical Foot and Ankle Service and Joe DiMaggio Sports Medicine Center at the Hospital for Special Surgery (HSS) and New York-Presbyterian Hospital/Weill Cornell Medical College in New York City, where he has been on staff since 1991.
He is internationally known for his non-surgical approach for the treatment of foot and ankle disorders and developing treatment protocols that prevent the progression of foot and ankle deformities using conservative treatment regimens such as prescription foot orthoses and physical therapy modalities. Most often these non-surgical regimens prevent the need for surgical intervention in the active patient.
In addition, Dr. Positano's Center at Hospital for Special Surgery in New York City also focuses on the effect that abnormal foot function has on the development of knee, hip and lower back disorders in the active and athletic population.
Dr. Positano was featured on the front page of the New York Times in an article concerning the dangers of cosmetic foot surgery. He has authored and edited numerous peer reviewed articles and has served as the editor of 11 orthopedic/medical/podiatric textbooks ranging from non- surgical foot and ankle orthopedics, heel disorders, sports medicine, foot and ankle disorder prevention and systemic disease manifestations in the foot, ankle and lower extremity.
Ann Prestipino, '80 M.P.H., Massachusetts General Hospital, Senior Vice President. Ann L. Prestipino currently serves as the Senior Vice President for Strategy and Clinical at the Massachusetts General Hospital (MGH) and the Massachusetts General Physicians Organization (MGPO) located in Boston, Massachusetts. Ann received her Bachelor of Arts Degree in Human Biology from Brown University and a master’s in public health degree from Yale University. She began working at the Massachusetts General Hospital during the 1980’s and has been there ever since. She began her career as the Assistant to the Director of Operations, moving on to the Administrative Director for Emergency Services and then becoming the Director of Patient Services. In 1989 Ann was promoted to the position of Assistant General Director for Surgical and Anesthesia Services and in 1992 became Vice President for these areas. In 2001 she was promoted to Senior Vice President. She has overseen a wide variety of clinical/academic departments as well as many centers of excellence over the course of her career. In her current role Ann is directly responsible for all administrative and financial aspects including the clinical, educational and research programs in the Department of Emergency Medicine, as well as related hospital departments including the emergency department, perioperative services and other procedural areas and health system engineering. In addition, she serves as the senior executive responsible for strategic planning for the MGH/MGPO. She serves as Senior Advisor to the Partners Emergency Preparedness Committee and chairs the MGH Emergency Preparedness Committee. She sits on a wide number of committees involved in both the overall administration of the hospital, the physician organization as well as Partners Healthcare System. She is also a Teaching Associate at Harvard Medical School in its Department of Anesthesia. In 2010, Ann was asked to establish the Office of Strategy Implementation for the Partners Healthcare System in addition to her MGH/MGPO role and served as its director on a part time basis until early 2013. She serves as chair of the Board of Trustees of Boston MedFlight, is a member the American College of Health Care Executives.
William B. Schultz, ‘70 BA , is a partner in the Washington, D.C. law firm Zuckerman Spaeder, where he focuses on complex regulatory litigation and provides strategic advice to companies and public interest organizations. He has worked for many years on reducing the use of tobacco products and controlling prescription drug prices. He also represents small biotechnology and generic drug companies, and individual scientists. Between 2011 and 2016, he was General Counsel of the Department of Health and Human Services. He is a member of the Committee on Science, Law and Technology, National Academy of Sciences, and for 10 years he taught at Georgetown University Law Center. He also is on the Board of the Center for Science in the Public Interest, the Board of the National Health Law Program and the Board of Trustees of Partners in Health. He was Deputy Assistant Attorney General, Civil Division, U.S. Department of Justice (1999-2000), Deputy Commissioner for Policy, Food and Drug Administration (1994-1999), and Counsel to the Subcommittee on Health and the Environment (Rep. Henry A. Waxman, chairman), Committee on Energy and Commerce, U.S. House of Representatives (1989-1994). From 1976 to 1989, Bill worked as a public interest lawyer at Public Citizen Litigation Group. He began his legal career clerking for Judge William B. Bryant, U.S. District Court, D.C. Bill received his undergraduate degree from Yale College and his law degree from the University of Virginia School of Law.
Sam K. Srivastava is Chief Operating Officer for Bright Health, a consumer-focused health insurance and technology company. Prior to joining Bright Health, Sam was Chief Executive Officer of Magellan Healthcare where he focused on improving health and affordability through advanced analytics and clinical solutions. He led the strategy development, operations, product development and management, and profitability and growth of Magellan Healthcare, while positioning Magellan as a leader in the behavioral health, Medicaid and specialty healthcare markets. Srivastava also provided leadership over enterprise strategy, communication and government affairs.
Previously, Srivastava worked at Cigna where he was president of the national and senior business segments. He had executive management responsibility for the strategic planning, business operations, growth and financial performance for these segments, which serve approximately 18 million individuals. He was instrumental in the acquisition of HealthSpring and the pharmacy benefit management partnership with CatamaranRx.
Srivastava has held executive leadership positions in the commercial, senior, low-income and disabled population segments at UnitedHealth Group and HealthNet and served as a management consultant in the United States and internationally, primarily focusing on the areas of developing and improving integrated health care delivery systems for providers, insurers and governments.
Srivastava graduated from Kent State University with a bachelor’s degree in medical science and humanities and completed graduate work at Yale University in healthcare management. He also sits on a number of advisory boards, including Oliver Wyman, Yale School of Public Health and Yale Healthcare Conference. He is married to Dr. Lisbet Lundsberg, a member of the faculty at the Yale School of Medicine, and resides in Wilton, Conn. with their four daughters.
David Thomas, Managing Partner, Court Square, has been a member of the Court Square Investment Team since 1980. Mr. Thomas received degrees in finance and accounting from the University of Akron. He is currently a director of Conterra Broadband, Golden State Medical Supply, Momentum Telecom, Mspark, National Seating & Mobility, and Smart City. He most recently served on the boards of Fibertech Networks, Harvard Drug Group, Wyle, Cadence Aerospace, Newmarket, and Auto Europe Group. Previous boards include Aviall, Brintec, C&H Sugar, DavCo Restaurants, The Devon Group, Flender, Furnishings International, Hancor Pipe, Interface Solutions, International Airmotive, MagnaChip Semiconductor, Mid-Atlantic Coca-Cola, NCI, Neenah Foundry, Pamida Stores, People Express Airlines, Smith Alarm, Worldspan, York International, and Zatarain’s.
George Tolis, M.D., ‘91 B.S., ’91 M.S., was born in Chicago, Illinois. He graduated from Yale University summa cum laude with a bachelor's and a master's degree in molecular biophysics and biochemistry. Following graduation from Harvard Medical School in 1995, he completed an internship and residency in general surgery at Massachusetts General Hospital and a fellowship in cardiothoracic surgery at Yale-New Haven Hospital. Dr. Tolis then completed an advanced aortic fellowship at Mount Sinai Hospital in New York City. Dr. Tolis worked at Lenox Hill Hospital in New York City as chief of aortic surgery and at St. Elizabeth's Medical Center as chief of the Division of Cardiothoracic Surgery. He joined the cardiac surgery staff at Mass General in July 2014.